胸导管引流在 HLA - 1 单倍型相同肾移植中的有益作用。

The beneficial effects of thoracic duct drainage in HLA-1 haplotype identical kidney transplantation.

作者信息

Ohshima S, Ono Y, Kinukawa T, Matsuura O, Takeuchi N, Hattori R

出版信息

J Urol. 1987 Jul;138(1):33-5. doi: 10.1016/s0022-5347(17)42978-8.

Abstract

The beneficial effects of pre-treatment thoracic duct drainage on graft survival in living related kidney transplantation are presented. Since July 1980 lymphocyte depletion through thoracic duct drainage has been used as pre-treatment therapy in 39 HLA-1 haplotype identical living related kidney transplant patients. Thoracic duct drainage was maintained for 29 to 49 days (mean 36 days) before transplantation and 52 to 215 times 10(9) cells (mean 130 times 10(9) cells) were removed. Postoperative immunosuppression consisted of azathioprine and steroids. Actuarial graft survival was 100 per cent at 3 months, 97 per cent at 6 months through 2 years, 92 per cent at 3 years and 57 per cent at 4 years after transplantation. Patient survival was 100 per cent at 3 months, 97 per cent at 6 months through 3 years and 86 per cent at 4 years. Pre-treatment thoracic duct drainage maintained for more than 28 days could have a significant role on the improvement of the graft survival in HLA-1 haplotype identical kidney transplantation.

摘要

本文介绍了预处理胸导管引流对亲属活体肾移植中移植物存活的有益作用。自1980年7月以来，通过胸导管引流进行淋巴细胞清除已被用作39例HLA-1单倍型相同的亲属活体肾移植患者的预处理疗法。在移植前，胸导管引流维持29至49天（平均36天），清除52至215×10⁹个细胞（平均130×10⁹个细胞）。术后免疫抑制包括硫唑嘌呤和类固醇。移植后3个月时移植物实际存活率为100%，6个月至2年为97%，3年为92%，4年为57%。患者存活率3个月时为100%，6个月至3年为97%，4年为86%。预处理胸导管引流维持超过28天对改善HLA-1单倍型相同肾移植中的移植物存活可能具有重要作用。